Eculizumab
| Use attributes for filter ! | |
| ChEMBL Id | 1201828 |
|---|---|
| Target | Complement |
| C5 | |
| Elimination half-life | 8 to 15 days (mean 11 days) |
| License data | EMA |
| INN | |
| US | |
| FDA | |
| Source | Humanized (from mouse) |
| ATC code | L04AA25 (WHO) |
| Date of Reg. | |
| Date of Upd. | |
| ID | 1189875 |
About Eculizumab
Eculizumab, sold under the trade name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and neuromyelitis optica.